Plasma KRAS as a biomarker for pancreatic ductal adenocarcinoma (PDAC).

被引：1
|
作者：
Krantz, Benjamin A.
Tsui, Dana
Lowery, Maeve Aine
Capanu, Marinela
Yu, Kenneth H.
Kelsen, David Paul
Gedvilaite, Erika
Zhang, Liguo
Selcuklu, S. Duygu
You, Daoqi
Pernicka, Jennifer S. Golia
Do, Richard K. G.
Iacobuzio-Donahue, Christine A.
O'Reilly, Eileen Mary
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] Trinity Coll Dublin, Dublin, Ireland
[3] Mem Sloan Kettering Canc Ctr, Weill Cornell Med Coll, 1275 York Ave, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 04期
关键词：
D O I：
10.1200/JCO.2018.36.4_suppl.316
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
316
引用
收藏
页数：1
相关论文
共 50 条
  • [41] MicroRNAs as Indicators of Malignancy in Pancreatic Ductal Adenocarcinoma (PDAC) and Cystic Pancreatic Lesions
    Prinz, Christian
    Fehring, Leonard
    Frese, Robin
    CELLS, 2022, 11 (15)
  • [42] Allelic ratio of KRAS mutations in pancreatic ductal adenocarcinoma
    Lennerz, Jochen K.
    Stenzinger, Albrecht
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [43] Critical role of KRAS mutation in pancreatic ductal adenocarcinoma
    Fan, Zhiyao
    Fan, Kun
    Yang, Chao
    Huang, Qiuyi
    Gong, Yitao
    Cheng, He
    Jin, Kaizhou
    Liu, Chen
    Ni, Quanxing
    Yu, Xianjun
    Luo, Guopei
    TRANSLATIONAL CANCER RESEARCH, 2018, 7 (06) : 1728 - 1736
  • [44] PATHOGENIC KRAS MUTATIONS PROFILE IN PANCREATIC DUCTAL ADENOCARCINOMA
    Iacob, Razvan
    Dima, Simona
    Sorop, Andrei
    Manea, Ioana
    Ionescu, Victor S.
    Spiridon, Andreea G.
    Stoica, Bianca
    Bunduc, Stefania
    Chiosa, Andrei
    Cazacu, Irina M.
    Croitoru, Vlad M.
    Chelaru, Raluca
    Iacob, Speranta
    Becheanu, Gabriel
    Dumbrava, Mona
    Herlea, Vlad
    Croitoru, Adina E.
    Csiki, Irma Eva
    Ceafalan, Laura C.
    Popescu, Irinel
    Gheorghe, Cristian
    GASTROENTEROLOGY, 2023, 164 (06) : S802 - S803
  • [45] Circulating levels of ADAM12, a stromal activation biomarker, are predictive of survival in pancreatic ductal adenocarcinoma (PDAC)
    van Laarhoven, H. W.
    Damhofer, H.
    Veenstra, V. L.
    Waasdorp, C.
    Van Rijssen, L. B.
    Dijk, F.
    Wilmink, J. W.
    Besselink, M. G.
    Busch, O. R.
    Medema, J. P.
    Li, J. Shiansong
    Jiang, R.
    Pierce, D. W.
    Bijlsma, M. F.
    ANNALS OF ONCOLOGY, 2017, 28
  • [46] Biomarker Panel for the Diagnosis of Pancreatic Ductal Adenocarcinoma
    Kim, Hongbeom
    Kang, Kyung Nam
    Shin, Yong Sung
    Byun, Yoonhyeong
    Han, Youngmin
    Kwon, Wooil
    Kim, Chul Woo
    Jang, Jin-Young
    CANCERS, 2020, 12 (06)
  • [47] Argyrin F therapy attenuates carcinogenesis of pancreatic ductal adenocarcinoma (PDAC)
    Barat, S.
    Xi, C.
    Bozko, P.
    Bui, K. C.
    Sipos, B.
    Kalesse, M.
    Malek, N. P.
    Plentz, R. R.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 11 - 11
  • [48] Prediction of response to pelareorep plus pembrolizumab in pancreatic ductal adenocarcinoma (PDAC).
    Fountzilas, Christos
    Wilkinson, Grey A.
    Eng, Kevin H.
    Fields, Paul
    Arora, Sukeshi Patel
    Kalinski, Pawel
    Raber, Patrick
    Nuovo, Gerard
    Coffey, Matthew C.
    Mahalingam, Devalingam
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [49] Clinicopathologic Characteristics and Biologic Behavior of Concurrent Pancreatic Ductal Adenocarcinoma (PDAC)
    Lew, M.
    Morales-Oyarvide, V.
    Liao, X.
    Ogino, S.
    Chen, J-H
    Pitman, M. B.
    Mino-Kenudson, M.
    LABORATORY INVESTIGATION, 2012, 92 : 446A - 446A
  • [50] Genomic characterization of ATM alterations in advanced pancreatic ductal adenocarcinoma (PDAC).
    Perera, Sheron
    Denroche, Robert Edward
    Holter, Spring
    Kelly, Deirdre
    Zhang, Amy
    Wang Yifan
    Dodd, Anna
    Ramotar, Stephanie
    Hutchinson, Shawn
    Tehfe, Mustapha
    Ramjeesingh, Ravi
    Biagi, James Joseph
    Wilson, Julie
    Notta, Faiyaz
    Fischer, Sandra
    Zogopoulos, George
    Grant, Robert C.
    Gallinger, Steven
    Knox, Jennifer J.
    O'Kane, Grainne M.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
12345